- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05834309
Exercise Effects on Health Status in Patients With Severe Mental Illness (SMI01)
November 7, 2023 updated by: Universidad Pública de Navarra
Effectiveness of a Multicomponent Exercise Program on Health Status and Health-related Quality of Life in Patients With Severe Mental Illness: Study Protocol for a Randomized Controlled Trial.
People with severe mental disorders have a mortality rate 2 to 3 times higher than that of the general population, largely due to the presence of comorbidities, with a predominance of cardiovascular disease.
This population has a higher risk of developing metabolic syndrome compared to the healthy population.
Several factors are involved.
The usual pharmacological treatment in people with severe mental disorder is a risk factor for the development of metabolic syndrome and deterioration of physical condition.
This is generally compounded by poor health care, high-calorie diets, a sedentary lifestyle, difficulties in coping with life situations that generate emotional states (anxiety and/or depression) that result in unhealthy lifestyle habits related to food, activity, interpersonal relationships, sleep, consumption habits (tobacco, alcohol and drugs) and other environmental factors.
Physical exercise has been proposed as one of the most effective treatments to reverse the negative consequences of low levels of physical activity in this population.
However, the mechanism of action of exercise on health status and the optimal "dose" and intensity of exercise to achieve the greatest number of benefits with respect to cardiometabolic health in patients with severe mental disorder are unknown.The study will be carried out at the Mental Health Rehabilitation Unit of Navarra, a center under the Mental Health Management of Osasunbidea, where people between 18 and 65 years of age with a diagnosis of severe mental illness in a situation of clinical stability receive treatment.The sample will be composed of 100 participants from consecutive admissions to the Rehabilitation Unit.
The subjects will be randomized into 2 groups; a control group that will receive the usual specialized care and an intervention group, which in addition to receiving the usual rehabilitation treatment, will undergo a 6-week multicomponent physical exercise program performed 2 days per week.
The effects of exercise on the inflammatory profile, metabolic parameters, physical condition, cognitive function, vascular function, muscle strength, health-related quality of life, lifestyle habits (diet, activation, sleep, substance use) and mood will be evaluated.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mikel Lopez Saez de Asteasu, PhD
- Phone Number: +34 848 423199
- Email: mikel.lopez.saezdeasteasu@gmail.com
Study Contact Backup
- Name: Mikel Izquierdo, PhD
- Phone Number: + 34 848 423199
- Email: mikel.izquierdo@unavarra.es
Study Locations
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Recruiting
- Complejo Hospitalario de Navarra
-
Contact:
- Juan Ignacio Arraras
-
Pamplona, Navarra, Spain, 31008
- Recruiting
- Fundacion Miguel Servet
-
Contact:
- Mikel Saez de Asteasu, PHD
- Email: mikel.lopez@unavarra.es
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- resident in Navarra
- diagnosis of severe mental disorder (DSM 5: Schizophrenia 295.90, Tr. Schizoaffective Disorder 295.70, Schizotypal Personality Disorder 301.22, Schizoid Personality Disorder 301.20, Schizophreniform Personality Disorder 295.40, Psychotic Disorder with Delusional Ideas 295.40, Psychotic Disorder with Delusional Ideas 295.40. Schizophreniform 295.40, Psychotic disorder with delusions 293.81, Psychotic disorder with hallucinations 293.82, Major depressive disorder 296.33, Bipolar disorder type I 296.44, Bipolar disorder type II 296.89, Obsessive Compulsive Disorder 300.
- primary nursing diagnosis NANDA and Virginia Henderson NOC 0099 Ineffective Health Maintenance
- at least one of the secondary nursing diagnoses 001 Nutritional Imbalance due to Excess, 003 Risk of Nutritional Imbalance due to Excess, 00096 Sleep Deprivation, 00146 Anxiety or 00168 Sedentary
- willing to voluntarily participate in the randomly assigned intervention, after signing the informed consent form.
Exclusion Criteria:
- acute illness that does not allow physical exercise sessions or assessments during the study
- medical contraindication that prevents physical exercise
- treatment with Interleukin-6 receptor antagonists (tocilizumab) during the last month due to drug interference with adaptations to cardiopulmonary exercise
- refusal to sign the informed consent form by the study subject
- impossibility of follow-up.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
Patients in this group will receive clinical usual care.
|
|
Experimental: Exercise training group
An individualized multicomponent exercise program including resistance, aerobic, balance and flexibility exercises.The duration of the sessions will be 45 minutes, and the duration of the whole program will be 6 weeks, equivalent to 12 sessions.
|
The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session.
The exercises will be performed at low intensity in the warm-up.
During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed.
All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity).
The rests between sets will be between 1 and 2 minutes.
At the end of the session, there will be a 5-minute return to calm by stretching.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of metabolic syndrome
Time Frame: 14 weeks
|
Any 3 of the 5 features: Waist circumference (> 102 cm men/ > 88 cm women),Elevated triglycerides (> 150 mg/dl), reduced HDL cholesterol (< 40 mg/dl men/ < 50 mg/dl women), elevated blood pressure(> 130 mmHg Systolic blood pressure or > 85 mmHg Diastolic blood pressure), and elevated fasting glucose (> 100 mg/dl) glucose.
|
14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Physical Activity Questionnaire (IPAQ)
Time Frame: 14 weeks
|
Physical activity questionnaire.
LOW If not moderate or vigorous.
MODERATE: 3 or more days of vigorous-intensity activity of at least 20 minutes per day OR b) 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR c) 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum T=total physical activity of at least 600 Metabolic equivalent of task (MET)-minutes/week.
HIGH a) Vigorous-intensity activity on at least 3 days (20min minimum, achieving a minimum Total physical activity of at least 1500 MET-minutes/week or 7 or more days of any combination of walking, moderate-intensity or vigorous-intensity activities achieving a minimum Total physical activity of at least 3000 MET-minutes/week.
|
14 weeks
|
Muscle strength
Time Frame: 14 weeks
|
Maximal dynamic strength (one-maximum muscle strength) was measured for four exercises (knee extension, leg press, row and bench press) using a Smart Strength machine (eGym GmbH, München, Germany).
Results were expressed in kilograms.
|
14 weeks
|
European Quality of Life-5 Dimensions (EuroQol-5D)
Time Frame: 14 weeks
|
Health related quality of life.The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The worse score is 0 and the best score is 100.
|
14 weeks
|
Physical condition
Time Frame: 14 weeks
|
Graded exercise tests will be performed on a bicycle ergometer (Lode B.V., Groningen, The Netherlands) to determine the maximal oxygen uptake (VO2max), measured by ml/kg/min.
|
14 weeks
|
Beck questionnaire
Time Frame: 14 weeks
|
Depression.
The minimum value is 0 points and the maximum value is 63 points.
Higher scores mean a worse outcome.
|
14 weeks
|
State Strait Anxiety Inventory (STAI)
Time Frame: 14 weeks
|
Anxiety.
The minimum score is 0 and the maximum score is 120.
Higher scores means a worse outcome.
|
14 weeks
|
Positive And Negative Syndrome Scale (PANSS)
Time Frame: 14 weeks
|
Positive and negative symptoms.
Positive scale (minimum score is 7 and maximum score is 49), negative scale (minimum scale is 7 and maximum score is 49) and general psychopathology scale (minimum score is 16 and maximum score is 112 points).
Higher scores means a worse outcome.
|
14 weeks
|
Screen for Cognitive Impairment in Psychiatry (SCIP)
Time Frame: 14 weeks
|
Cognitive function.
Memory, attention, executive function and processing speed.
|
14 weeks
|
Adverse events related to medication
Time Frame: 14 weeks
|
Neurological side effects related to the medication assessed by the Side Effect Rating Scale.
|
14 weeks
|
Muscle mass
Time Frame: 14 weeks
|
Muscle thickness by ultrasound examination
|
14 weeks
|
Densitometry
Time Frame: 14 weeks
|
Body composition
|
14 weeks
|
Medication
Time Frame: 14 weeks
|
Pharmacologic/antipsichotic treatment (i.e., pills consumption) associated with the disorder obtained by the medical history.
|
14 weeks
|
Blood pressure
Time Frame: 14 weeks
|
Blood pressure will be assessed using a Vasera 2000 device (Fukuda Denshi, Japan).
|
14 weeks
|
Oviedo questionnaire
Time Frame: 14 weeks
|
Sleep quality.The insomnia subscale ranges from 9 to 45, where a higher scores means increased severity of insomnia.
|
14 weeks
|
Schizophrenia Quality of Life Scale Revision 4 (SQLS-R4)
Time Frame: 14 weeks
|
Health related quality of life.The SQLS-R4 is a self-report measure comprising 33 items from which two domains of quality of life, psychosocial feelings (22 items) and cognition and vitality (11 items) are derived.
The items are scored on a 5-point frequency-response Likert scale (''never'', ''rarely'', ''sometimes'', ''often'', ''always'').
A total score of both domains can also be calculated and individual domain and total scores are standardized by scoring algorithm to a 0 - 100 scale.
Higher SQLS-R4 scores indicate comparatively lower quality of life.
|
14 weeks
|
The Matrics Consensus Cognitive Battery
Time Frame: At baseline
|
Cognitive function.The MATRICS Consensus Cognitive Battery should be used as the standard battery for all clinical trials of potential cognition-enhancing agents for schizophrenia.
|
At baseline
|
Medical history of substance abuse
Time Frame: 14 weeks
|
Alcohol consumption, use of drugs and other substances.
|
14 weeks
|
Vascular stiffness
Time Frame: 14 weeks
|
Cardio-ankle vascular index (CAVI) will be estimated by brachial-ankle oscillometry using a Vasera 2000 device (Fukuda Denshi, Japan) as marker of vascular stiffness.
|
14 weeks
|
Vascular stiffness
Time Frame: 14 weeks
|
Pulse wave velocity (PWV) will be estimated by brachial-ankle oscillometry using a Vasera 2000 device (Fukuda Denshi, Japan).
|
14 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ana Urteaga, Complejo Hospitalario de Navarra
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 5, 2022
Primary Completion (Actual)
March 5, 2023
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
March 7, 2023
First Submitted That Met QC Criteria
April 17, 2023
First Posted (Actual)
April 28, 2023
Study Record Updates
Last Update Posted (Estimated)
November 9, 2023
Last Update Submitted That Met QC Criteria
November 7, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPNavarra
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Mayo ClinicCompleted
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Physical exercise
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Universidade Estadual da ParaibaUniversity of Campinas, BrazilUnknown
-
Instituto de Cardiologia do Rio Grande do SulFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, BrazilTerminatedObesity | Sedentary Lifestyle | Hypercholesterolemia | High Blood PressureBrazil
-
Clarice Maria de Lucena MartinsCompletedMetabolic Diseases | Physical Activity
-
McGill UniversityUniversité du Québec à Trois-Rivières; Université de Montréal; Concordia University... and other collaboratorsRecruiting
-
National Research Centre for the Working Environment...CompletedMusculoskeletal DisordersDenmark
-
Cardiff UniversityCompletedParkinson's DiseaseUnited Kingdom
-
Instituto Materno Infantil Prof. Fernando FigueiraCompleted
-
Universidad Católica San Antonio de MurciaCompleted
-
Göteborg UniversityVastra Gotaland Region; Sahlgrenska University Hospital, SwedenCompletedChronic Widespread PainSweden